38070-79-0

Basic information

• Product Name: PYRIDINE-2,3-DIMETHANOL
• Synonyms: PYRIDINE-2,3-DIMETHANOL;PYRIDINE-2,3-DIYLDIMETHANOL;2,3-Pyridinedimethanol;2,3-bis(hydroxyMethyl)pyridine;2,3-DihydroxyMethylpyridine
• CAS NO: 38070-79-0
• Molecular Formula: C₇H₉NO₂
• Molecular Weight: 139.15
• EINECS: 1312995-182-4
• Mol File: 38070-79-0.mol

Chemical Properties

• Boiling Point: 315.631 °C at 760 mmHg
• Flash Point: 144.689 °C
• Appearance: /
• Density: 1.261
• Vapor Pressure: 0.000182mmHg at 25°C
• Refractive Index: 1.59
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 13.51±0.10(Predicted)
• CAS DataBase Reference: PYRIDINE-2,3-DIMETHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: PYRIDINE-2,3-DIMETHANOL(38070-79-0)
• EPA Substance Registry System: PYRIDINE-2,3-DIMETHANOL(38070-79-0)

Safety Data

• Hazardous Substances Data: 38070-79-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
PYRIDINE-2,3-DIMETHANOL is used as a chemical intermediate for the synthesis of various pharmaceuticals. Its unique chemical structure allows it to be a key component in the development of new drugs and medications.
Used in Pesticide Industry:
In the pesticide industry, PYRIDINE-2,3-DIMETHANOL is utilized as a chemical intermediate in the production of various pesticides. Its properties contribute to the effectiveness of these products in controlling and eliminating pests.
Used as a Solvent:
PYRIDINE-2,3-DIMETHANOL is used as a solvent in certain industrial processes. Its ability to dissolve other substances makes it a valuable component in various applications, including the manufacturing of paints, coatings, and adhesives.
Used as a Stabilizer:
In some industrial applications, PYRIDINE-2,3-DIMETHANOL is employed as a stabilizer. Its presence helps to maintain the stability and consistency of products, ensuring their quality and performance over time.

Upstream product

• 605-38-9 dimethyl 2,3-pyridinedicarboxylate 
• 89-00-9 Pyridine-2,3-dicarboxylic acid 
• 64-17-5 ethanol 

Downstream Products

• 4733-69-1 furo[3,4-b]pyridine-7(5H)-one 
• 45754-12-9 2,3-bis(chloromethyl)-pyridine 
• 523993-95-5 methyl (+/-)-6-(4-methoxybenzenesulfonyl)-5,6,7,8-tetrahydro[1,6]naphthylidine-7-carboxylate 
• 27221-49-4 2,3-bis(chloromethyl)pyridine hydrochloride 
• 1246472-65-0 C₉H₁₃NO₆S₂ 
• 4663-93-8 pyridine-2,3-dicarbaldehyde 
• 253-73-6 pyrido<2,3-d>pyridazine 
• 220001-81-0 diethyl 5,7?dihydro?6H?cyclopenta[b]pyridine?6,6?dicarboxylate 

Relevant articles and documents

Pyridine bioisosteres of potent GluN2B subunit containing NMDA receptor antagonists with benzo[7]annulene scaffold

It has been reported that benzo [7]annulen-7-amines bearing electron withdrawing substituents such as 3d with a 2-Cl or 3e with a 2-NO2 moiety show very high affinity towards the ifenprodil binding site of GluN2B subunit containing NMDA receptors. Therefore, bioisosteres of 3 with an electron deficient pyridine ring instead of the chloro- or nitrobenzene ring were envisaged. Starting from pyridine-2,3-dicarboxylic acid (5) a five-step synthesis of the key intermediate, the ketone 10, was developed. Reductive amination with various primary amines and NaBH(OAc)3 led to the homologous secondary amines 11a-c. Subsequent methylation yielded the tertiary amines 12b and 12c. Receptor binding studies with [3H]ifenprodil revealed Ki-values above 100 nM for the most active phenylpropyl- and phenylbutylamines 11b and 11c. The >100-fold reduced GluN2B affinity of pyridines 11b and 11c compared to the GluN2B affinity of the corresponding chloro- and nitrobenzene derivatives 3d and 3e indicates that the pyridine ring is not tolerated as bioisosteric replacement of the chloro- or nitrobenzene ring in this type of compounds.

USP30 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of USP30, and the treatment of USP30-mediated disorders.

IDO/TDO Inhibitor

A compound of formula (I) given below or a pharmaceutically acceptable salt of the compound is useful as an IDO/TDO inhibitor. Thus, the compound of formula (I) or the pharmaceutically acceptable salt of the compound can be used as, for example, a therapeutic agent for a disease or a disorder selected from tumor, infectious disease, neurodegenerative disorder, cataract, organ transplant rejection, autoimmune disease, postoperative cognitive impairment, and disease related to women's reproductive health [in the following formula (I), ring A represents an aromatic ring, an aliphatic ring, a heterocyclic ring, or a condensed ring of two or more rings selected from an aromatic ring, an aliphatic ring and a heterocyclic ring; X, R1 and R2 represent a substituent on a ring atom constituting ring A; m represents an integer of 0 to 6; X represents, for example, a halogen atom; and R1 and R2 are the same or different and are selected from, for example, the group consisting of groups of formula (a) or formula (b); and in the following formula (a) and formula (b), Y is selected from the group consisting of O, S, and Se, Z is selected from the group consisting of O, S, and Se, n represents an integer of 1 to 8, r represents an integer of 1 to 8, s represents an integer of 1 to 8, R4 represents, for example, —C(═NH)—HN2, and R6 represents, for example, a substituted or unsubstituted aryl group].

A conformationally restricted GABA analogue based on octahydro-1H-cyclopenta[b]pyridine scaffold

An approach to rel-(4aS,6R,7aR)-octahydro-1H-cyclopenta[b]pyridine-6-carboxylic acid—a bicyclic conformationally restricted γ-aminobutyric acid (GABA) analogue was developed. The eight-step sequence relied on the reaction of 2,3-bis(chloromethyl)pyridine and a C1-binucleophile and the catalytic reduction of the pyridine ring as the key steps and allowed for the preparation of the title compound in 9.0% overall yield. Assessment of the octahydro-1H-cyclopenta[b]pyridine scaffold geometry showed that this template can be considered truly three-dimensional.

Coplanar tetracyclic π-excess σ2P ligands

The acid-catalyzed reactions of 5-methyl-2-phosphanylaniline (1) with dialdehydes were studied. Whereas the reaction with glyoxal provides a mixture of two 1H-1,3-benzazaphospholes, 2 and 3, by concomitant reduction of a CHO group and C-C bond cleavage, respectively, the reaction with o-phthalic dicarbaldehyde provided in excellent yield the tetracyclic planar benzazaphosphole 4, which was characterized by crystal structure analysis. The active hydrogen atoms, delivered by aromatization of a dihydrobenzazaphosphole intermediate, forms an N-CH2 bridge by reductive N-alkylation. Pyridine-2,6-dicarbaldehyde reacts analogously but not chemoselectively and, thus, gives two isomers 5 and 6. Condensation with pyridine-2,6-dicarbaldehyde afforded the bis(benzazaphosphole)pyridine pincer ligand 7, but along with 2-(benzazaphospholyl)-6-tolylpyridine (8) by partial P-C bond cleavage. The high upfield 31P NMR chemical shift of 4 compared to those of normal benzazaphospholes indicates it to be a particularly π-rich σ2P ligand. Aromatization-driven acid-catalyzed condensations of the N,P-diprimary compound 1 with dialdehydes are coupled with hydrogen transfer reactions. With glyoxal and pyridine-2,6-dicarbaldehyde this gives rise to side products, but with o-C6H4(CHO)2, high yields of 4 are obtained. π-Delocalization through the coplanar aryl rings causes high π-density at the phosphorus atom.

THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1 comprising administering to a subject in need thereof a compound described here.

The mechanism of unexpected reduction of dimethyl pyridine-2,3- dicarboxylate to 1,2,3,4-tetrahydrofuro[3,4-b]pyridin-5(7H)-one with sodium borohydride

An unexpected reduction of dimethyl pyridine-2,3-dicarboxylate to 1,2,3,4-tetrahydrofuro[3,4-b]pyridin-5(7H)-one with sodium borohydride in ethanol and tetrahydrofuran, respectively, is described, a hypothetic mechanism for the unusual reductive product is proposed.

A facile synthesis of 2,3-azaisoindoline

2,3-Azaisoindoline (4) was prepared via reaction of dichloride 11 with 2,4-dimethoxybenzyl amine followed by deprotection with trifluoroacetic acid and triethylsilane. Isolation of the unstable 2,3-azaisoindoline 4 was facilitated by conversion to the bis-HCl salt.

ANTIMICROBIAL HETEROCYCLIC COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS

The present invention provides heterocyclic compounds of the following formula (I) : or pharmaceutically acceptable salts, prodrugs, solvates, or hydrates thereof useful as antibacterial agents, pharmaceutical compositions containing them, methods for their use, and methods for preparing these compounds.

Synthesis and structure-activity relationships of 5,6,7,8-tetrahydropyrido[3,4-b]pyrazine-based hydroxamic acids as HB-EGF shedding inhibitors

HB-EGF Shedding inhibitors have been expected to become effective medicines for skin diseases caused by the proliferation of keratinocytes. In order to discover novel HB-EGF shedding inhibitors and clarify their structure-activity relationships, 5,6,7,8-tetrahydronaphthylidine-based hydroxamic acid and 5,6,7,8-tetrahydropyrido[3,4-b]pyrazine-based hydroxamic acids have been synthesized. Among the synthesized compounds, the ethoxyethoxy derivative 3o and the methoxypropoxy derivative 3p exhibited much more potent HB-EGF shedding inhibitory activity than CGS 27023A. The structural modification of 5,6,7,8-tetrahydropyrido[3,4-b]pyrazine-based hydroxamic acids enabled us to establish the following structure-activity relationships; the existences of the hydroxamic acid, the sulfonamide, and the phenyl moieties are crucial for a potent HB-EGF shedding inhibitory activity, and the stereochemistry of the alpha carbon of hydroxamic acid is also important. In addition, from the comparison of their HB-EGF shedding inhibitory activities with their MMPs inhibitory activities, we found that the S1′ pocket of the responsible enzyme for HB-EGF shedding is deep unlike that of MMP-1.